Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 3

Status

Completed 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myeloid, Acute 62Myelodysplastic Syndromes 33Leukemia, Myelomonocytic, Chronic 16Leukemia 16Recurrence 9Lymphoma, Large B-Cell, Diffuse 6Leukemia, Myelomonocytic, Acute 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Monocytic, Acute 5Hodgkin Disease 5Myeloproliferative Disorders 4Congenital Abnormalities 4Anemia, Refractory, with Excess of Blasts 4Thrombocythemia, Essential 3Primary Myelofibrosis 3Polycythemia Vera 3Lymphoma 3Blast Crisis 3Triple Negative Breast Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasm, Residual 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Carcinoma, Renal Cell 2Breast Neoplasms 2Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cyclophosphamide 37fludarabine phosphate 33Peripheral Blood Stem Cell Transplantation 29Methotrexate 27Busulfan 26Tacrolimus 24Cytarabine 21Antilymphocyte Serum 20Cyclosporine 19Mycophenolic Acid 18Whole-Body Irradiation 17Radiotherapy 15Methylprednisolone 15Filgrastim 13merphos 10Melphalan 10Cord Blood Stem Cell Transplantation 10Imatinib Mesylate 9Etoposide 9Granulocyte Colony-Stimulating Factor 7Thiotepa 6Rituximab 6sargramostim 5fludarabine 5Vincristine 5Sirolimus 5Prednisone 5Idarubicin 5Cladribine 5thymoglobulin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Blast Crisis × Decitabine × Clear all
NCT04188405 2026-06-05

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

M.D. Anderson Cancer Center

Phase 2 Completed
20 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

NCT00042003 2024-08-02

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Astex Pharmaceuticals, Inc.

Phase 2 Completed
40 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00054431 2013-01-23

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
80 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡